KEVIN F. MCLAUGHLIN - 23 Sep 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role
SVP, CFO and Treasurer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin
Issuer symbol
XLRN
Transactions as of
23 Sep 2021
Net transactions value
-$3,011,252
Form type
4
Filing time
24 Sep 2021, 19:36:42 UTC
Next filing
22 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $75,425 +2,500 +23% $30.17* 13,181 23 Sep 2021 Direct F1
transaction XLRN Common Stock Options Exercise $397,978 +9,800 +74% $40.61* 22,981 23 Sep 2021 Direct F1
transaction XLRN Common Stock Options Exercise $305,221 +7,330 +32% $41.64* 30,311 23 Sep 2021 Direct F1
transaction XLRN Common Stock Sale $2,988,368 -18,647 -62% $160.26 11,664 23 Sep 2021 Direct F1, F2
transaction XLRN Common Stock Sale $158,519 -983 -8.4% $161.26 10,681 23 Sep 2021 Direct F1, F3
transaction XLRN Common Stock Options Exercise $211,172 +5,200 +49% $40.61* 15,881 24 Sep 2021 Direct F1
transaction XLRN Common Stock Options Exercise $7,079 +170 +1.1% $41.64* 16,051 24 Sep 2021 Direct F1
transaction XLRN Common Stock Sale $861,241 -5,370 -33% $160.38 10,681 24 Sep 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -2,500 -48% $0.000000 2,663 23 Sep 2021 Common Stock 2,500 $30.17 Direct F1, F5
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -9,800 -37% $0.000000 16,462 23 Sep 2021 Common Stock 9,800 $40.61 Direct F1, F6
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -7,330 -26% $0.000000 20,670 23 Sep 2021 Common Stock 7,330 $41.64 Direct F1, F7
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5,200 -32% $0.000000 11,262 24 Sep 2021 Common Stock 5,200 $40.61 Direct F1, F6
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -170 -0.82% $0.000000 20,500 24 Sep 2021 Common Stock 170 $41.64 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.10 to $161.35 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.08 to $160.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5 The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017.
F6 The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.
F7 The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019.